NCT00708942 - Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Cervical Intraepithelial Neoplasia

Interventions

DRUG

Hexaminolevulinate (HAL)

Drug: hexaminolevulinate (HAL) Suppository HAL 100 mg for 3-7 hours application

DRUG

Placebo

Placebo suppository, for 3-7 hours application

DRUG

Hexaminolevulinate (HAL)

Drug: hexaminolevulinate (HAL) Ointment HAL 100 mg for 5 hours application

DRUG

Placebo

Placebo ointment for 5 hours application

Trial Locations (5)

Department of Obstetrics and Gyneacology, Lille University Hospital, Lille

Department of Obstetrics and Gynecology, Hanover

Fritzøe klinikk, Larvik

Department of Obstetrics and Gynaecology, Ullevål University Hospital, Oslo

Medicus, Trondheim